Thanks JD, appreciate your comments and your contrary points...

Thanks JD, appreciate your comments and your contrary points which are well made. I don't mean to suggest CU6 deserves to go back to $300M just because it historically traded there - they've made advances, had some good results, two complete responses etc. There's a lot to like here from what I can see. I also agree that the climb began before the capital raise; from the chart it really kicked off from late 2023 when it climbed from $300M to $795M just prior to the raise (this also shows that management were smart to raise into strength, and minimize dilution at the time).

What I am suggesting is that to look at this at current prices and think it feels 'cheap', because of an extremely precipitous fall, could be quite a mistake. Sentiment always goes too far each way. In this case, positive sentiment launched it to $2.7B or 10X where it had traded less than 12 months before (well done to anyone on that ride who got off). But in like manner, negative sentiment can overshoot too, and send it much lower than $700M - maybe not back to where it was, but perhaps close - especially when they're trading cum-raise in 9-12 months or so. That's the problem with these speculative biotechs; without any earnings fundamentals, you're over-reliant on sentiment during these long stretches between results readouts, and it can swing to extremes each way. Just my thoughts, I'll leave it there and check in at the next result-related announcement. Fingers crossed they can do great things in this space and good luck to all.